Gyre Therapeutics, Inc.GYRENASDAQ

Revenue (LTM)

$117M

+10.2% YoY

Net Income (LTM)

$19M

+57.2% YoY

Free Cash Flow

$-180000

Revenue CAGR (5Y)

+41.0%

Marginsimproving

FCF($0.0B)

Profitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	7	102↑1294.0%	113↑10.9%	106↓6.8%	117↑10.2%
Gross Profit	-0	97↑29466.6%	109↑11.6%	102↓6.4%	111↑9.1%
Operating Income	-84	9↑111.0%	-67↓830.5%	16↑124.0%	11↓28.9%
Net Income	-88	2↑102.6%	-93↓4137.1%	12↑113.0%	19↑57.2%
EBITDA	-88	10↑111.8%	20↑96.7%	18↓12.3%	14↓21.4%
EPS Diluted	-2.87	0.03↑101.0%	-1.41↓4800.0%	0.05↑103.5%	0.02↓55.0%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	44	25↓43.2%	34↑33.1%	12↓64.7%	37↑213.8%
Total Current Assets	51	50↓3.5%	57↑15.2%	65↑13.2%	102↑58.0%
Total Assets	56	85↑52.3%	117↑37.5%	125↑7.6%	166↑32.5%
Total Current Liabilities	14	12↓13.6%	20↑63.8%	20↓2.6%	18↓6.3%
Total Liabilities	15	13↓14.0%	103↑718.4%	27↓73.7%	24↓11.7%
Total Equity	41	43↑3.5%	-16↓137.2%	63↑500.0%	106↑67.5%
Total Debt	2	1↓74.3%	0↓33.3%	2↑290.7%	1↓41.2%
Net Debt	-42	-25↑41.5%	-33↓34.8%	-10↑69.1%	-36↓253.7%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-84	11↑112.7%	26↑142.5%	-4↓114.1%	1↑127.7%
Capital Expenditure	-1	-5↓495.7%	-9↓71.8%	-3↑63.6%	-1↑62.0%
Free Cash Flow	-85	6↑106.7%	17↑204.7%	-7↓139.1%	-0↑97.3%
Stock-Based Comp	3	13↑292.5%	7↓45.5%	1↓88.6%	7↑761.3%
Net Change in Cash	14	-5↓135.9%	8↑265.8%	-22↓360.3%	25↑216.4%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance